IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors.
Future Oncol
; 5(3): 305-8, 2009 Apr.
Article
en En
| MEDLINE
| ID: mdl-19374537
ABSTRACT
Evaluation of Rebouissou S, Amessou M, Couchy G et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009). Recently, in-frame somatic deletions activating gp130, the receptor of IL-6, have been identified in inflammatory hepatocellular adenomas. This is a novel class of mutation in a receptor that is central to the IL-6/gp130/STAT3 pathway, which is relevant in a variety of cancers. STAT3 is a cancer transcriptional node activating several prosurvival and proliferation genes. The activation of IL-6/gp130 also promotes the activation of the RAS and PI3K pathways. Intriguingly, the overexpression of IL-6 and STAT3 has been observed in lung adenocarcinomas, including those with EGF-receptor mutations. Further clinical research should be performed on the IL-6/gp130/STAT3 signaling axis, since it constitutes an autocrine and paracrine amplification loop in several tumors, including those with RAS mutations.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Future Oncol
Año:
2009
Tipo del documento:
Article
País de afiliación:
España